<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01137591</url>
  </required_header>
  <id_info>
    <org_study_id>AAAD4090</org_study_id>
    <nct_id>NCT01137591</nct_id>
  </id_info>
  <brief_title>Acetaminophen in Combination With N-Acetylcysteine (NAC) Versus Placebo in Treating Fever</brief_title>
  <official_title>Acetaminophen in Combination With N-Acetylcysteine (NAC) vs. Placebo in the Treatment of Fever: A Double-Blind, Randomized Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy of the an N-acetyl-p-aminophenol (APAP,
      also known as acetaminophen) and N-acetylcysteine (NAC) combination versus an APAP-placebo
      combination as an anti-pyretic agent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      N-acetyl-p-aminophenol (APAP), or more commonly known as acetaminophen in the United States,
      accounts for more overdose and overdose deaths in the United States and United Kingdom than
      any other pharmaceutical agent. If N-acetylcysteine (NAC) is given within 8 to 10 hours of
      APAP ingestion, it has been shown to prevent serious liver failure and death in the setting
      of overdoses. Therefore, it may be beneficial to administer APAP in combination with NAC
      routinely to reduce rates of liver failure and death. Because NAC's main role is to reduce
      the accumulation of APAP's toxic metabolites, the concomitant administration of NAC should
      have no impact on the efficacy of APAP as an antipyretic and analgesic. Thus, we propose a
      single-center, non-inferiority randomized control study comparing the efficacy of the
      APAP-NAC combination as compared to APAP-placebo as an anti-pyretic agent.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Unable to recruit sufficient participants due to lack of funding; PI has left the institution.
  </why_stopped>
  <start_date>April 2009</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in temperature reduction between participants who are administered combination N-acetyl-p-aminophenol and N-Acetylcysteine (APAP-NAC) versus combination APAP-placebo</measure>
    <time_frame>6 hours after study drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference in liver function tests after study drug administration between participants who are administered combination N-acetyl-p-aminophenol and N-Acetylcysteine (APAP-NAC) versus combination APAP-placebo</measure>
    <time_frame>Within 24 hours of study drug administration</time_frame>
    <description>Change in serum total protein (TP), albumin (Alb), total bilirubin (TB), direct bilirubin (DB), amino alanine aminotransferase (ALT), aspartate aminotransferase (AST) and alkaline phosphatate (AP) levels before and after the study drug administration.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Liver Failure</condition>
  <condition>Liver Failure, Acute</condition>
  <condition>Drug Induced Liver Injury</condition>
  <condition>Prevention &amp; Control</condition>
  <condition>Fever</condition>
  <arm_group>
    <arm_group_label>APAP and NAC combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-acetyl-p-aminophenol and placebo (APAP-NAC) combination pill</description>
  </arm_group>
  <arm_group>
    <arm_group_label>APAP and Placebo combination</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>N-acetyl-p-aminophenol and placebo (APAP-placebo) combination pill</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APAP and NAC combination</intervention_name>
    <description>APAP 650mg and NAC 600mg combination oral tablet administered once</description>
    <arm_group_label>APAP and NAC combination</arm_group_label>
    <other_name>APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol</other_name>
    <other_name>NAC: n-acetylcysteine; Mucomyst</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>APAP and Placebo</intervention_name>
    <description>APAP 650mg and Placebo combination oral tablet administered once</description>
    <arm_group_label>APAP and Placebo combination</arm_group_label>
    <other_name>APAP: n-acetyl-p-aminophenol; acetaminophen; Tylenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults aged 18 to 75 years old

          -  admitted to an inpatient unit at Columbia-Presbyterian Medical Center

          -  fever defined as an oral temperature of 38.5Â°C

        Exclusion Criteria:

          -  if oral temperature cannot be obtained

          -  abnormal aminotransferase levels

          -  prior adverse reaction to acetaminophen or N-acetylcysteine
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Chang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/ency/article/002598.htm</url>
    <description>Acetaminophen overdose information from the NIH</description>
  </link>
  <reference>
    <citation>Bronstein AC, Spyker DA, Cantilena LR Jr, Green J, Rumack BH, Heard SE. 2006 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS). Clin Toxicol (Phila). 2007 Dec;45(8):815-917.</citation>
    <PMID>18163234</PMID>
  </reference>
  <reference>
    <citation>Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). N Engl J Med. 1988 Dec 15;319(24):1557-62.</citation>
    <PMID>3059186</PMID>
  </reference>
  <reference>
    <citation>Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet. 1995 Aug 26;346(8974):547-52. Review.</citation>
    <PMID>7658783</PMID>
  </reference>
  <verification_date>March 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2010</study_first_submitted>
  <study_first_submitted_qc>June 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 4, 2010</study_first_posted>
  <last_update_submitted>March 3, 2015</last_update_submitted>
  <last_update_submitted_qc>March 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acetaminophen</keyword>
  <keyword>Acetylcysteine</keyword>
  <keyword>Antidotes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fever</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Chemical and Drug Induced Liver Injury</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

